These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 738649)
1. Effect of estrogen treatment on coagulation and fibrinolysis in postmenopausal women. With special reference to cold activation of factor VII. Gjønnaess H; Munkeby I; Frølich W; Vennerød AM; Fagerhol MK Gynecol Obstet Invest; 1978; 9(2-3):109-23. PubMed ID: 738649 [TBL] [Abstract][Full Text] [Related]
2. Studies on plasma coagulation and fibrinolysis during oral contraception of various types with special reference to cold activation of factor VII. Gjonnaess H; Fagerhol MK Scand J Haematol; 1974; 12(3):232-40. PubMed ID: 4831827 [TBL] [Abstract][Full Text] [Related]
3. Components of the kallikrein-kinin system and the spontaneous cold activation of factor VII in human plasma. Laake K; Gjonnaess H; Fagerhol MK Acta Pharmacol Toxicol (Copenh); 1973; 33(3):229-40. PubMed ID: 4800785 [TBL] [Abstract][Full Text] [Related]
4. Studies on coagulation and fibrinolysis in pregnancy, with special reference to cold activation of factor VII. Gjonnaess H; Fagerhol MK Acta Obstet Gynecol Scand; 1975; 54(4):363-7. PubMed ID: 1081809 [TBL] [Abstract][Full Text] [Related]
6. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens]. Winkler UH; Krämer R; Kwee B; Schindler AE Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837 [TBL] [Abstract][Full Text] [Related]
7. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Zegura B; Keber I; Sebestjen M; Koenig W Atherosclerosis; 2003 May; 168(1):123-9. PubMed ID: 12732395 [TBL] [Abstract][Full Text] [Related]
8. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495 [TBL] [Abstract][Full Text] [Related]
10. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ Menopause; 2008; 15(2):248-55. PubMed ID: 17693902 [TBL] [Abstract][Full Text] [Related]
11. Coagulation and fibrinolysis in estrogen-treated surgically menopausal women. Notelovitz M; Kitchens CS; Ware MD Obstet Gynecol; 1984 May; 63(5):621-5. PubMed ID: 6326012 [TBL] [Abstract][Full Text] [Related]
12. Coagulative and fibrinolytic studies on postmenopausal women treated with a new non-steroidal oestrogen. Kullander S; Svanberg L; Astedt B Acta Obstet Gynecol Scand; 1977; 56(4):371-4. PubMed ID: 74933 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. Eilertsen AL; Sandvik L; Mowinckel MC; Andersen TO; Qvigstad E; Sandset PM Thromb Res; 2007; 120(3):371-9. PubMed ID: 17156824 [TBL] [Abstract][Full Text] [Related]
14. 17-beta-oestradiol and the fibrinolytic activity on vein walls. Astedt B; Jeppsson S J Obstet Gynaecol Br Commonw; 1974 Sep; 81(9):719-23. PubMed ID: 4138043 [TBL] [Abstract][Full Text] [Related]
15. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Zegura B; Guzic-Salobir B; Sebestjen M; Keber I Menopause; 2006; 13(4):643-50. PubMed ID: 16837886 [TBL] [Abstract][Full Text] [Related]
16. Changes in coagulation factors in postmenopausal women on ethinyl oestradiol. Hunter DJ; Anderson AB; Haddon M Br J Obstet Gynaecol; 1979 Jun; 86(6):488-90. PubMed ID: 465400 [TBL] [Abstract][Full Text] [Related]
17. Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel. Sabra A; Bonnar J J Reprod Med; 1983 Jan; 28(1 Suppl):85-91. PubMed ID: 6834350 [TBL] [Abstract][Full Text] [Related]
18. Oestrogen concentrations in plasma, endometrium, myometrium and vagina of postmenopausal women, and effects of vaginal oestriol (E3) and oestradiol (E2) applications. van Haaften M; Donker GH; Haspels AA; Thijssen JH J Steroid Biochem; 1989 Oct; 33(4A):647-53. PubMed ID: 2811377 [TBL] [Abstract][Full Text] [Related]
19. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women. Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143 [TBL] [Abstract][Full Text] [Related]
20. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Siegbahn A; Ruusuvaara L Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]